Laurus Labs Ltd Stock Price Today (NSE: LAURUSLABS)
Fundamental Score
Laurus Labs Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Laurus Labs Ltd share price today is ₹1013.40, up +0.00% on NSE/BSE as of 17 February 2026. Laurus Labs Ltd (LAURUSLABS) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹55.57K (Cr). The 52-week high for LAURUSLABS share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 81.25x, LAURUSLABS is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 7.45% and a debt-to-equity ratio of 0.46.
Laurus Labs Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Laurus Labs Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Laurus Labs Share Price: A ROCE-Focused Analysis
The pharmaceutical sector is currently experiencing a bifurcation, with API manufacturers like Laurus Labs facing pricing pressures while branded generics and innovative research firms are commanding premium valuations. This analysis examines the current valuation of Laurus Labs, focusing primarily on its Return on Capital Employed (ROCE). The current Laurus Labs share price stands at ₹950.549988, trading at a Price-to-Earnings (PE) ratio of 81.25. A critical element of our assessment is the company's ROCE, currently reported at 9.15%.
A ROCE of 9.15% indicates the efficiency with which Laurus Labs is utilizing its capital to generate profits. This figure is crucial in evaluating the long-term sustainability and competitive advantage of the business. While a higher ROCE generally implies a stronger "economic moat," allowing a company to fend off competitors and maintain profitability, 9.15% warrants closer inspection, especially when compared to industry peers. The ability of Laurus Labs to improve its ROCE will be a key determinant in its future valuation.
Considering sector peers, we can draw preliminary comparative insights. For example,
Mankind Pharma Ltd, known for its robust brand portfolio and strong domestic distribution network, may command a higher PE ratio, in part due to perceived superior management quality and execution. This is based on observational data of management's historical decisions in capital allocation, efficiency management and market navigation, and may not be conclusive. The management quality is a qualitative element of our analysis, which is further weighted through financial ratios.The 9.15% ROCE directly impacts Laurus Labs' competitive advantage. A lower ROCE than peers suggests that the company may be less efficient in deploying capital, which could limit its ability to invest in future growth initiatives, such as research and development or capacity expansion. Companies like Smruthi Organics Ltd or Balaxi Pharmaceuticals Ltd, which likely have different ROCE profiles, provides context of what is potentially achievable. Improved operational efficiency and strategic capital allocation could bolster ROCE, potentially driving positive momentum for the Laurus Labs share price. A deeper understanding of ROCE drivers is crucial for prospective investors.
This financial analysis is part of a comprehensive 80-parameter fundamental audit, verified by Sweta Mishra, focusing on the ROCE efficiency of Laurus Labs. This is an observational analysis based on publicly available financial data and should not be construed as investment advice.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Laurus Labs Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of LAURUSLABS across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Strong Operating Margins (24.27%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (882.71%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (35.12%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (14.42% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Interest Coverage (5.56x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹140.11 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Strong Institutional Confidence (FII+DII: 37.89%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Risk Factors
6 factors identified
Below-Average Return on Equity (7.45%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (9.15%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 81.25x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Weak Earnings Growth (4.38% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (4.56% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Low Promoter Commitment (27.59%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
Laurus Labs Ltd Financial Statements
Comprehensive financial data for Laurus Labs Ltd including income statement, balance sheet and cash flow
About LAURUSLABS (Laurus Labs Ltd)
Laurus Labs Ltd (LAURUSLABS) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹55.57K (Cr). Laurus Labs Ltd has delivered a Return on Equity (ROE) of 7.45% and a ROCE of 9.15%. The debt-to-equity ratio stands at 0.46, reflecting the company's capital structure. Investors tracking LAURUSLABS share price can monitor key metrics including P/E ratio, promoter holding of 27.59%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
Latest News
LAURUSLABS Share Price: Frequently Asked Questions
What is the current share price of Laurus Labs Ltd (LAURUSLABS)?
As of 17 Feb 2026, 10:14 am IST, Laurus Labs Ltd share price is ₹1013.40. The LAURUSLABS stock has a market capitalisation of ₹55.57K (Cr) on NSE/BSE.
Is LAURUSLABS share price Overvalued or Undervalued?
LAURUSLABS share price is currently trading at a P/E ratio of 81.25x, compared to the industry average of 31.77x. Based on this relative valuation, the Laurus Labs Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of LAURUSLABS share price?
The 52-week high of LAURUSLABS share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Laurus Labs Ltd share price?
Key factors influencing LAURUSLABS share price include quarterly earnings growth (Sales Growth: 35.12%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Laurus Labs Ltd a good stock for long-term investment?
Laurus Labs Ltd shows a 5-year Profit Growth of 4.56% and an ROE of 7.45%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.46 before investing in LAURUSLABS shares.
How does Laurus Labs Ltd compare with its industry peers?
Laurus Labs Ltd competes with major peers in the Pharmaceuticals. Investors should compare LAURUSLABS share price P/E of 81.25x and ROE of 7.45% against the industry averages to determine competitive standing.
What is the P/E ratio of LAURUSLABS and what does it mean?
LAURUSLABS share price has a P/E ratio of 81.25x compared to the industry average of 31.77x. Investors pay ₹81 for every ₹1 of annual earnings.
How is LAURUSLABS performing according to Bull Run's analysis?
LAURUSLABS has a Bull Run fundamental score of 45.6/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does LAURUSLABS belong to?
LAURUSLABS operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Laurus Labs Ltd share price.
What is Return on Equity (ROE) and why is it important for LAURUSLABS?
LAURUSLABS has an ROE of 7.45%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Laurus Labs Ltd generates profits from shareholders capital.
How is LAURUSLABS debt-to-equity ratio and what does it indicate?
LAURUSLABS has a debt-to-equity ratio of 0.46, which indicates moderate leverage that should be monitored.
What is LAURUSLABS dividend yield and is it a good dividend stock?
LAURUSLABS offers a dividend yield of 0.12%, meaning you receive ₹0.12 annual dividend for every ₹100 invested in Laurus Labs Ltd shares.
How has LAURUSLABS share price grown over the past 5 years?
LAURUSLABS has achieved 5-year growth rates of: Sales Growth 14.42%, Profit Growth 4.56%, and EPS Growth 4.38%.
What is the promoter holding in LAURUSLABS and why does it matter?
Promoters hold 27.59% of LAURUSLABS shares, with 2.69% pledged. High promoter holding often indicates strong management confidence in Laurus Labs Ltd.
What is LAURUSLABS market capitalisation category?
LAURUSLABS has a market capitalisation of ₹55570 crores, placing it in the Large-cap category.
How volatile is LAURUSLABS stock?
LAURUSLABS has a beta of N/A. A beta > 1 suggests the Laurus Labs Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is LAURUSLABS operating profit margin trend?
LAURUSLABS has a 5-year average Operating Profit Margin (OPM) of 24.27%, indicating the company's operational efficiency.
How is LAURUSLABS quarterly performance?
Recent quarterly performance shows Laurus Labs Ltd YoY Sales Growth of 35.12% and YoY Profit Growth of 882.71%.
What is the institutional holding pattern in LAURUSLABS?
LAURUSLABS has FII holding of 26.17% and DII holding of 11.72%. Significant institutional holding often suggests professional confidence in the Laurus Labs Ltd stock.